Trial Profile
A Phase 2, Randomized, Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Bupivacaine (Primary) ; Bupivacaine/meloxicam (Primary) ; Bupivacaine/meloxicam (Primary) ; Meloxicam (Primary)
- Indications Perioperative pain
- Focus Therapeutic Use
- Sponsors Heron Therapeutics
- 13 Sep 2023 Number of treatment arms has been changed from 23 to 22.
- 26 Sep 2017 Status changed from active, no longer recruiting to completed.
- 31 Mar 2017 Status changed from recruiting to active, no longer recruiting.